Migraine sufferers may have hope for a more productive livelihood, according to a recent PhRMA article.
Author and Senior Director of policy and research at PhRMA Samantha Dougherty says that a new study found that if everyone who suffers from migraines used newly-emerging treatments the U.S. could save as much as $396 billion annually and avoid 374 million migraine days per year. The drugs, known as calcitonin gene-related peptide (CGRP) inhibitors, are the first medicines developed specifically to prevent migraines.
About one in six Americans suffer from migraines, with effects that could only be described as debilitating. Dougherty cites a recent report revealing that 68 percent of employed migraine sufferers are less productive at work, and 72 percent reported that migraines affect their ability to care for loved ones.